Loading data for INAB — first visit, this takes a few seconds.
IN8bio Inc. (INAB)
NasdaqCM: INAB
· Real-Time Price · USD
1.03
-0.01 (-0.96%)
At close: Aug 28, 2026, 3:55 PM
1.04
+0.82%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
IN8bio Inc. (INAB) Stock Price, Analysis & Data
-0.96% (1D)
| Bid | 0.75 |
| Market Cap | 10.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.67M |
| 0.28 | |
| -1.28 | |
| n/a | |
| -1.07 | |
| P/B (ttm) | 0.56 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 7, 2025 |
| Ask | 1.33 |
| Volume | 23,999 |
| Avg. Volume (20D) | 59,579 |
| Open | 1.04 |
| Previous Close | 1.04 |
| Day's Range | 1.03 - 1.05 |
| 52-Week Range | 0.88 - 2.73 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INAB
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical tria...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 18
Stock Exchange NasdaqCM
Ticker Symbol INAB
Website https://in8bio.com
Financial Performance
In 2025, IN8bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -19.44M, a decrease of -36.13%.
Financial StatementsEarnings Surprise
IN8bio has released their quarterly earnings on Aug 6, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.25 exceeds estimates by 0.12, with 79.84% YoY growth.
IN8bio Inc. is scheduled to release its earnings on Aug 7, 2025, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
